Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dietary counseling versus sevelamer carbonate in early chronic kidney disease: effects on FGF-23
2011-005107-33Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Mar 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of sevelamer carbonate in chronic kidney disease (CKD) and phosphorus metabolism disorder (2 arms), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Differences in variation in circulating FGF-23 levels between groups. Started Mar 2012; status: active.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)phosphorus metabolism disorder
Beyond the preview
Go deeper on 2011-005107-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005107-33.